Biophytis S.A. is a clinical-stage biotechnology company that is primarily focused on developing therapies for age-related diseases and chronic conditions. Headquartered in Paris, France, and with operations extending to the United States, Biophytis is renowned for its work in advancing treatments that address sarcopenia, a condition characterized by muscle degeneration in the elderly, and other significant health issues associated with aging. The company's flagship development programs aim to utilize its expertise in cellular biology and regenerative medicine to innovate drug therapies that improve muscle function and overall quality of life for patients. Biophytis plays a vital role in the biopharmaceutical sector by pushing the boundaries of traditional medicine with its focus on novel therapeutic approaches. By participating in international collaborative research efforts and leveraging its robust scientific platform, Biophytis contributes significantly to the advancement of medical interventions for unmet needs in geriatric health care, thereby holding substantial potential in the biotechnology and pharmaceutical markets.